IDH2 and chondrosarcoma: IDH inhibitors are also currently under investigation in phase I clinical trials in chondrosarcoma; however, these early results of ongoing trials are modest in terms of patients’ benefits, with a longer-term analysis required to assess the definitive effect on survival.